Diligence memo · auto-generated · as of July 3, 2026

Nynex Therapeutics, LLC

Nynex Therapeutics, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Nynex Therapeutics, LLC operates in Pharmaceuticals, based in CLEVELAND.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Nynex Therapeutics, LLC has raised $650K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $650K on 2017-03-05.

Most recent recorded round closed around 2017-03-05.

Valuation (modeled)modeled

Provath models Nynex Therapeutics, LLC at approximately $31M (range $364K–$349M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.62× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 9.3 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 15% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 34% of those peers.

Closest niche peers: Essentia Pharma Socal, Llc, Essentia Pharma Florida, Llc, Novellus LLC, Blake Insomnia Therapeutics, Inc., Eleusis Benefit Corporation, PBC.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.